Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke

Suspended

Phase 2 Results N/A

Eligibility Criteria

Inclusion Criteria

- 35-75 hospitalized patients
- Patients with acute stroke ≤24h
- NIHSS score 6-20 at time of enrollment , the score ≥2 of item 5 and/or 6
- For the first time or always without obvious sequelae of stroke disease(mRS≤1)
- Informed consent

Exclusion Criteria

- The disease such as Acute intracerebral hemorrhage,tumor and encephalitis which cause similar symptoms
- Patient with NIHSS level of consciousness score≥2 or dementia,or other patients who the investigator think that don't fit into the study
- TIA
- Symptoms of disease rapidly improving during the randomized
- Severe hypertension(SBP > 200 mmHg or DBP >110 mmHg)
- Inadequate liver function(AST or ALT greater than 2 times the upper limit of normal values);Renal impairment (Creatinine clearance <60ml/min)
- Severe system or viscera organic disease
- Have used other neuroprotectant or other experimental drugs
- Patient who are unlikely to complete the study that due to a severe clinical condition
- Pregnant or breast-feeding
- Participation in a previous clinical study within 30 days
- Meets all other exclusion criteria